See more : Hyulim ROBOT Co.,Ltd. (090710.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Day One Biopharmaceuticals, Inc. (DAWN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Day One Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ZEB Nickel Corp. (ZBNIF) Income Statement Analysis – Financial Results
- Emu NL (EMU.AX) Income Statement Analysis – Financial Results
- Interactive Financial Services Limited (IFINSER.BO) Income Statement Analysis – Financial Results
- Skydeck Acquisition Corp. Warrants (SKYAW) Income Statement Analysis – Financial Results
- Hatsuho Shouji Co.,Ltd. (7425.T) Income Statement Analysis – Financial Results
Day One Biopharmaceuticals, Inc. (DAWN)
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 383.00K | 531.00K | 199.00K | 155.00K | 0.00 |
| Gross Profit | -383.00K | -531.00K | -199.00K | -155.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 130.52M | 85.62M | 43.58M | 9.10M | 13.90M |
| General & Administrative | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Other Expenses | 1.00 | -18.00K | -15.00K | -31.00K | -2.00K |
| Operating Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Cost & Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Interest Income | 17.19M | 4.75M | 4.00K | 30.00 | 2.08K |
| Interest Expense | 0.00 | 4.75M | 4.00K | 30.00K | 2.08M |
| Depreciation & Amortization | 383.00K | 531.00K | 199.00K | 155.00K | 14.91M |
| EBITDA | -206.06M | -141.65M | -72.56M | -43.66M | -2.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -206.06M | -146.91M | -72.74M | -13.78M | -14.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.15M | 4.73M | -11.00K | -30.06M | -2.08M |
| Income Before Tax | -188.92M | -142.18M | -72.75M | -43.84M | -16.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.01M | -2.31M | -3.34M | -2.27M |
| Net Income | -188.92M | -132.18M | -70.44M | -40.51M | -14.71M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| EPS Diluted | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Weighted Avg Shares Out | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
| Weighted Avg Shares Out (Dil) | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that...
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head,...
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share a year ago.
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif.
SUNDECK 3200 HERALDS IN A NEW DAWN FOR HURRICANE BOATS
ELKHART, Ind. , Oct. 30, 2024 /PRNewswire/ -- Hurricane Boats, legendary innovator in versatile deck boat designs, ushers in the next chapter in its storied history with the launch of its latest model for 2025 – the SunDeck 3200.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will...
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.
Source: https://incomestatements.info
Category: Stock Reports